Any feedback?
Please rate this page
(literature.php)
(0/150)

BRENDA support

Literature summary for 3.4.21.92 extracted from

  • Zhang, Y.; Maurizi, M.R.
    Mitochondrial ClpP activity is required for cisplatin resistance in human cells (2016), Biochim. Biophys. Acta, 1862, 252-264 .
    View publication on PubMedView publication on EuropePMC
Search for more literature for 3.4.21.92

Application

Application Comment Organism
medicine reducing the levels of mitochondrial ClpP or ClpX renders human cancer cells more sensitive to cisplatin. ClpP levels are elevated in cervical carcinoma cells (KB-CP20) and hepatoma cells (BEL-7404-CP20) independently selected for cisplatin resistance Homo sapiens

Protein Variants

Protein Variants Comment Organism
S97A inactive. Overexpression has no effect on sensitivity of cells to cisplatin Homo sapiens

Localization

Localization Comment Organism GeneOntology No. Textmining
mitochondrion
-
 Homo sapiens 5739
-

Organism

Organism UniProt Comment Textmining
Homo sapiens Q16740
-
-

Source Tissue

Source Tissue Comment Organism Textmining
BEL-7404-CP20 cell
-
 Homo sapiens
-
KB-CP20 cell
-
 Homo sapiens
-

General Information

General Information Comment Organism
physiological function reducing the levels of mitochondrial ClpP or ClpX renders human cancer cells more sensitive to cisplatin. Overexpression of ClpP desensitizes cells to cisplatin. Cisplatin resistance correlates with decreased cellular accumulation of cisplatin and decreased levels of diguanosine-cisplatin adducts in both mitochondrial and genomic DNA. Higher levels of cisplatin-DNA adducts are found in cells in which ClpP has been depleted. Changes in the levels of ClpP have no effect on the levels of copper transporter CTR1. The levels of copper efflux pumps ATP7A and ATP7B are increased when ClpPwas overexpressed Homo sapiens